Net Loss Per Share

9 Months Ended

Sep. 30, 2025

Note 5—Net loss per share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:


	Three months ended September 30						Nine months ended September 30
	2025			2024			2025			2024
Numerator:
Net loss attributable to common stockholders	$	(7,104,544	)	$	(6,544,294	)	$	(23,296,928	)	$	(16,651,671	)
Denominator:
Weighted-average common shares outstanding - basic and diluted		50,666,430			12,178,522			46,235,423			12,176,127
Net loss per share attributable to common shareholders - basic and diluted	$	(0.14	)	$	(0.54	)	$	(0.50	)	$	(1.37	)

Common stock warrants in the amount of 297,029 issued to our financial advisor, H.C. Wainwright & Co., LLC, were not outstanding as shares of common stock as of September 30, 2025, however included in the weighted-average common shares outstanding – basic and diluted as if they were considered outstanding.

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. For the three months ended September 30, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period because including them would have had an anti-dilutive effect:


	As of September 30
	2025		2024
Preferred Series A (as converted)		-		7,053,338
Preferred Series A-1 (as converted)		-		4,500,142
Preferred Series B (as converted)		-		5,359,363
Convertible Notes (as converted)		-		8,222,297
Stock options issued and outstanding		6,494,441		3,301,894
Unvested restricted stock units		57		-
Warrants		13,088,461		10,671,099
Total		19,582,959		39,108,133

TuHURA Biosciences, Inc./NV 10-Q